Egyptian Liver Journal

Table 2 Direct-acting antivirals (DAAs) regimens in the studied groups

From: Impact of sustained virologic response in regression of portal hypertension in Egyptian patients with hepatitis C virus-associated cirrhosis and portal hypertension

Treatment protocol	Groups		Fisher’s exact test
	Group A	Group B	Fisher’s exact test
	N (%)	N (%)	p-value	Sig.
SOF/DAC	1 (2.5%)	32 (80%)	0.557	NS
SOF/DAC/RBV	35 (87.5%)	4 (10%)
SOF/DAC/RBV/SIM	2 (5%)	1 (2.5%)
PAR/OMB/RBV	2 (5%)	2 (5%)
PAR/OMB/RBV/SOF	0 (0%)	1 (2.5%)

Back to article page